223P Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)
Under an Elsevier user license
open archive
Cited by (0)
Copyright © 2020 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.